TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36071463

Group type: EXPERIMENTAL
Intervention: Digital psychosocial intervention (Viva Vida) delivered via WhatsApp, sending psychoeducational and behavioural activation audio and visual messages 4 days a week for 6 weeks.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group receiving a single message with general information about depression.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Digital psychosocial intervention (Viva Vida)
Number of subjects: 500
Study: 33865218

Group type: EXPERIMENTAL
Intervention: Stroboscopic balance training (SG)
Number of subjects: 39
Study: 35227311

Group type: EXPERIMENTAL
Intervention: Therapeutic mammoplasty
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 20
Study: 34521398

Group type: EXPERIMENTAL
Intervention: Curcumin nanomicelle capsules 80 mg twice a day for 7 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo two times a day for 7 weeks
Number of subjects: 50
Study: 35606094

Group type: EXPERIMENTAL
Intervention: 1-hour nap opportunity (8 + 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2-hour nap opportunity (7 + 2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 9 hours in bed overnight without a nap opportunity (9 + 0)
Number of subjects: 12
Study: 33607625

Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR, n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON, n = 6)
Number of subjects: 12
Study: 32701820

Group type: EXPERIMENTAL
Intervention: Age-specific risk scores for women aged 18-24
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age-specific risk scores for women aged 25-35
Number of subjects: 0

Group type: COMPARATOR
Intervention: VOICE risk score applied to women aged 18-35
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-1 incidence among women aged 18-24
Number of subjects: 0
Study: 35840303

Group type: EXPERIMENTAL
Intervention: Video intervention 1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Video intervention 2
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 3
Study: 33608413

Group type: EXPERIMENTAL
Intervention: Smart Beginnings (SB) intervention including Video Interaction Project (VIP) and Family Check-Up
Number of subjects: 403
Study: 35738297

Group type: EXPERIMENTAL
Intervention: Video-based training (self-learning using digital instructional materials)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stationary microsurgical course with tutor supervision
Number of subjects: 80
Study: 32101271

Group type: EXPERIMENTAL
Intervention: Olanzapine and sertraline
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo and sertraline
Number of subjects: 88
Study: 34996948

Group type: EXPERIMENTAL
Intervention: MCALP group: 0.5 g of methylprednisolone intravenously for three consecutive days at the beginning of the course and 3rd month, oral prednisone at a dose of 15 mg every other day for 6 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: FP group: 0.8-1.0 mg/kg/days of prednisone (maximum 70 mg/day) for 2 months, then tapered by 5 mg every 10 days for the next 4 months
Number of subjects: 87
Study: 34776174

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise for 2 weeks, 40 min/session, 3 sessions/week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 32819927

Group type: EXPERIMENTAL
Intervention: Oral vitamin B12 (1 mg/day in weeks 1-8, 1 mg/week in weeks 9-52)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Intramuscular vitamin B12 (1 mg on alternate days in weeks 1-2, 1 mg/week in weeks 3-8, 1 mg/month in weeks 9-52)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Oral vitamin B12
Number of subjects: 283

Group type: COMPARATOR
Intervention: Intramuscular vitamin B12
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Quality of life and adverse effects
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Patient preferences
Number of subjects: 283
Study: 35993635

Group type: EXPERIMENTAL
Intervention: TAP block with bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-TAP block
Number of subjects: 60
Study: 34626927

Group type: EXPERIMENTAL
Intervention: LB 266 mg TAP block alone
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: ITM 50 μg followed by LB 266 mg TAP block
Number of subjects: 153

Group type: COMPARATOR
Intervention: ITM 150 μg alone
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: LB 266 mg TAP block alone and LB + ITM group
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: LB + ITM group
Number of subjects: 153

Group type: COMPARATOR
Intervention: ITM group
Number of subjects: 153
Study: 36753778

Group type: EXPERIMENTAL
Intervention: MLM-CBRN Preparedness Program
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study: 33629258

Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic receptor antagonist)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 32474473

Group type: EXPERIMENTAL
Intervention: Matured Hop Bitter Acids (MHBA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34063799

Group type: EXPERIMENTAL
Intervention: Motivational plus family weight loss (M + FWL) intervention
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 241
Study: 33248594

Group type: EXPERIMENTAL
Intervention: HL group (high-low Zn, basal diets supplemented 120 mg/kg Zn)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: LH group (low-high Zn, basal diets supplemented 120 mg/kg Zn)
Number of subjects: 162
Study: 35714722

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Existing institutional patient educational material (PEM)
Number of subjects: 30
Study: 32919915

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 881

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 881
Study: 35653412

Group type: EXPERIMENTAL
Intervention: TFTD→Rego group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: TFTD+Bev→Rego group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Rego→TFTD group
Number of subjects: 69
Study: 32476445

Group type: EXPERIMENTAL
Intervention: Costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microfracture (MFx)
Number of subjects: 30
Study: 35617520

Group type: EXPERIMENTAL
Intervention: napabucasin plus paclitaxel
Number of subjects: 714

Group type: COMPARATOR
Intervention: placebo plus paclitaxel
Number of subjects: 714
Study: 33824441

Group type: EXPERIMENTAL
Intervention: Inpatient palliative care intervention during HCT
Number of subjects: 160
Study: 32925145

Group type: EXPERIMENTAL
Intervention: Hospital-based work support intervention in female breast and gynaecological cancer survivors
Number of subjects: 65

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 65
Study: 35656777

Group type: EXPERIMENTAL
Intervention: Darolutamide with ADT and docetaxel
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Placebo with ADT and docetaxel
Number of subjects: 1306
Study: 34282267

Group type: EXPERIMENTAL
Intervention: Mecobalamin intramuscular injections (0.5 mg/day, 3 times/week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mecobalamin oral tablets (1.5 mg/day)
Number of subjects: 32
Study: 33130252

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 15 min) to the prefrontal cortex
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study: 36432469

Group type: EXPERIMENTAL
Intervention: P-CHO (20 g of Pronativ®, native whey protein and 60 g of carbohydrate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO (80 g of carbohydrate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: P-CHO
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: P-CHO and CHO
Number of subjects: 12

Group type: COMPARATOR
Intervention: PLA (nonenergetic chocolate‐flavored drink)
Number of subjects: 12
Study: 32339048

Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional trans‐nasal trans‐speculum (TNTS) septoplasty
Number of subjects: 60
Study: 35396528

Group type: EXPERIMENTAL
Intervention: Ischemic condition (4.5 min ischemia + 0.5 min reperfusion)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition (no ischemia)
Number of subjects: 10
Study: 35623611

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs) for 4 hours per day for 60 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Number of subjects: 72
Study: 33341644

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 244

Group type: COMPARATOR
Intervention: no‐CPAP
Number of subjects: 244
Study: 32469384

Group type: EXPERIMENTAL
Intervention: Savolitinib (600 mg orally once daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sunitinib (50 mg orally once daily for 4 weeks, followed by 2 weeks without treatment)
Number of subjects: 60
Study: 33251910

Group type: EXPERIMENTAL
Intervention: eltrombopag
Number of subjects: 150
Study: 32243609

Group type: EXPERIMENTAL
Intervention: 37.5 mg daily oral iron
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 193
Study: 34033125

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF)
Number of subjects: 82

Group type: COMPARATOR
Intervention: GIC along with fluoride varnish (FV)
Number of subjects: 82
Study: 32718800

Group type: EXPERIMENTAL
Intervention: Enhanced Antenatal Care (EAC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual antenatal care
Number of subjects: 32
Study: 32375553

Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 11222
Study: 35811090

Group type: EXPERIMENTAL
Intervention: Vestibular socket therapy (VST) (test; n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Contour augmentation (control; n=20)
Number of subjects: 40
Study: 33938478

Group type: EXPERIMENTAL
Intervention: Withholding enteral feeds during packed red blood cell (PRBC) transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuing enteral feeds during packed red blood cell (PRBC) transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restricting enteral feeds during packed red blood cell (PRBC) transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withholding feeds during PRBC transfusions
Number of subjects: 0
Study: 32476816

Group type: EXPERIMENTAL
Intervention: Artificial tears and 0.1% fluorometholone eye drops three times a day (G-DESOS group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Artificial tears only (C-DESOS group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: N/A (CMDE and control groups)
Number of subjects: 39
Study: 616270988

Group type: EXPERIMENTAL
Intervention: BoNT‐A + intensive physiotherapy (iPT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Only intensive physiotherapy (iPT)
Number of subjects: 65
Study: 34075784

Group type: EXPERIMENTAL
Intervention: Yukon Choice PC (biodegradable polymer-based sirolimus-eluting stents)
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Xience (permanent polymer-based everolimus-eluting stents)
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: Patients without diabetes mellitus
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: Definite/probable stent thrombosis
Number of subjects: 1951
Study: 33273644

Group type: EXPERIMENTAL
Intervention: Sufentanyl target infusion based on the pupillary pain index
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard sufentanyl target infusion left to the discretion of the anesthesiologist (Control)
Number of subjects: 50
Study: 35477731

Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose (IV iron)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 32871095

Group type: EXPERIMENTAL
Intervention: Moderately hypocaloric Mediterranean diet
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care group (standard pediatric recommendations)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 121
Study: 34083348

Group type: EXPERIMENTAL
Intervention: Active NMES
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo NMES
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Usual care (home-based exercise, weekly telephone support, breathlessness management leaflet) with either placebo or active NMES for 6 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Qualitative findings from purposively sampled participants
Number of subjects: 22
Study: 35985109

Group type: EXPERIMENTAL
Intervention: Self-collection using Neoteryx Mitra Clamshell, n = 136
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Self-collection using Tasso-SST, n = 176
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Self-collection using Neoteryx Mitra Clamshell and Tasso-SST
Number of subjects: 312
Study: 34138615

Group type: EXPERIMENTAL
Intervention: Self-persuasion intervention (verbalize vaccination reasons)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Self-persuasion intervention (choose HPV topics)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Autonomous motivation scores
Number of subjects: 161
Study: 32588429

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy (PBC)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Non-platinum-based chemotherapy (non-PBC)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: PBC doublets
Number of subjects: 495

Group type: COMPARATOR
Intervention: Non-PBC doublets
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: PBC in first-line therapy
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: PBC
Number of subjects: 495
Study: 34717535

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g (P group)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg IVI (D group)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (C group)
Number of subjects: 300
Study: 32108181

Group type: EXPERIMENTAL
Intervention: Breakfast Session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late-evening Snack Session
Number of subjects: 0
Study: 32964807

Group type: EXPERIMENTAL
Intervention: 3D-QSAR models (CoMFA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3D-QSAR models (CoMSIA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3D-QSAR models (test set)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Docking studies (new designed compound C2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: ADMET properties analysis
Number of subjects: 26
Study: 33956703

Group type: EXPERIMENTAL
Intervention: Pramipexole (n=31), initiated at 0.125 mg 2 times a day, increased to a target of 4.5 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n=29)
Number of subjects: 60
Study: 34726501

Group type: EXPERIMENTAL
Intervention: Banaba (500 mg) twice a day for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 32939597

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35553855

Group type: EXPERIMENTAL
Intervention: Resistance training (80 min, 3 days per week for 12 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (maintained daily lifestyle without training)
Number of subjects: 30
Study: 33148767

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (IDC) - 6 months, three times per week, progressive, moderate intensity
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 124
Study: 36309399

Group type: EXPERIMENTAL
Intervention: 3D-LC
Number of subjects: 200

Group type: COMPARATOR
Intervention: MC
Number of subjects: 200
Study: 34325924

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% eye drops from India
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% eye drops from DRC
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% eye drops from developing countries (India and DRC)
Number of subjects: 7
Study: 32418078

Group type: EXPERIMENTAL
Intervention: Adjuvant transarterial infusion chemotherapy (TAI) with FOLFOX regimen
Number of subjects: 127

Group type: COMPARATOR
Intervention: Follow-up without any adjuvant treatment (FU group)
Number of subjects: 127
Study: 36258223

Group type: EXPERIMENTAL
Intervention: StOP?‐protocol intervention group
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Standard of care (control) group
Number of subjects: 14000
Study: 32107337

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2) given concurrently prior to each infusional EPOCH cycle
Number of subjects: 106

Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2) given sequentially (weekly for 6 weeks) following completion of EPOCH
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: EPOCH chemotherapy (96-hour IV infusion of etoposide, doxorubicin, vincristine plus oral prednisone followed by IV bolus cyclophosphamide every 21 days for 4 to 6 cycles)
Number of subjects: 106
Study: 33731656

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Concurrent Exercise (CE)
Number of subjects: 9
Study: 32713846

Group type: EXPERIMENTAL
Intervention: CT colonography (CTC), n=302
Number of subjects: 953

Group type: COMPARATOR
Intervention: Colonoscopy (CC), n=346
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Capsule endoscopy (CE), n=305
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: No investigation
Number of subjects: 953
Study: 33399050

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (RT) with Gloreha device
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 24
Study: 32203229

Group type: EXPERIMENTAL
Intervention: High-medium glycemic index (hGI) rice (GI: 86)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Medium-high glycemic index (mGI) rice (GI: 62)
Number of subjects: 189
Study: 36124455

Group type: EXPERIMENTAL
Intervention: Acupotomy treatment on pain points around knee joint, once a week for 3 weeks.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Celecoxib capsule, 200 mg orally once a day for 3 weeks (western medicine group).
Number of subjects: 110
Study: 34405978

Group type: EXPERIMENTAL
Intervention: Abbreviated mindfulness practice course
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study: 35167364

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care control (n=12)
Number of subjects: 24
Study: 33236043

Group type: EXPERIMENTAL
Intervention: Peanut group (56 g/d as snacks, n=113)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (isocaloric white rice bars, n=111)
Number of subjects: 224
Study: 32645021

Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 0
Study: 33739211

Group type: EXPERIMENTAL
Intervention: Early adolescent sexual desire (EASD) measure
Number of subjects: 542
Study: 34085476

Group type: EXPERIMENTAL
Intervention: ZHU Lian's type‐Ⅰ inhibition acupuncture combined with Zhuang medicinal thread moxibustion
Number of subjects: 66

Group type: COMPARATOR
Intervention: Valaciclovir hydrochloride tablets, mecobalamin tablets, and vitamin B1 tablets
Number of subjects: 66
Study: 32028286

Group type: EXPERIMENTAL
Intervention: 10-day quadruple concomitant regimen
Number of subjects: 364

Group type: COMPARATOR
Intervention: 14-day quadruple concomitant regimen
Number of subjects: 364
Study: 34738660

Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg sc monthly, n = 17)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg sc daily, n = 19)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (sc monthly, n = 20)
Number of subjects: 56
Study: 34289666

Group type: EXPERIMENTAL
Intervention: MicroHeat with endodontic sealer (Mseal)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MicroHeat without endodontic sealer (Mnoseal)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: System B with endodontic sealer (SBseal)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: System B without endodontic sealer (SBnoseal)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Positive control (Ct+)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Negative control (Ct-)
Number of subjects: 38
Study: 35645797

Group type: EXPERIMENTAL
Intervention: Fosaprepitant (150 mg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Palonosetron (75 μg)
Number of subjects: 88
Study: 33016570

Group type: EXPERIMENTAL
Intervention: High frequency spinal cord stimulation (10 kHz)
Number of subjects: 126
Study: 32828116

Group type: EXPERIMENTAL
Intervention: Low vitamin D3 supplementation (4200 IU/week)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High vitamin D3 supplementation (28,000 IU/week)
Number of subjects: 80
Study: 36074106

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 33289649

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus axitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib monotherapy
Number of subjects: 0
Study: 36269291

Group type: EXPERIMENTAL
Intervention: Biofeedback and music training programme (BMT programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32797298

Group type: EXPERIMENTAL
Intervention: rt-PA (intravenous recombinant tissue-plasminogen activator)
Number of subjects: 1638

Group type: COMPARATOR
Intervention: No rt-PA
Number of subjects: 1638
Study: 34889858

Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod 0.024%
Number of subjects: 23
Study: 33185131

Group type: EXPERIMENTAL
Intervention: increase MVPA intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: decrease sedentary behavior active control
Number of subjects: 204
Study: 32253894

Group type: EXPERIMENTAL
Intervention: Multimodal exercise program for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70